News
RLAY
6.37
+3.49%
0.22
Weekly Report: what happened at RLAY last week (0415-0419)?
Weekly Report · 5d ago
Weekly Report: what happened at RLAY last week (0408-0412)?
Weekly Report · 04/15 10:08
Relay Therapeutics to Participate in Upcoming Investor Conferences
Barchart · 04/11 15:05
FATE, ALPN and RLAY are among after hour movers
On the Move FATE, ALPN and RLAY are among after hour movers. Rallybio Corporation and Alpine Immune Sciences are among the biggest gainers. Performant Financial and NioCorp Developments are the biggest losers in the after hour.
Seeking Alpha · 04/10 21:20
12 Health Care Stocks Moving In Wednesday's After-Market Session
Rallybio shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by 10.52% during the session.
Benzinga · 04/10 20:31
Weekly Report: what happened at RLAY last week (0401-0405)?
Weekly Report · 04/08 10:11
Weekly Report: what happened at RLAY last week (0325-0329)?
Weekly Report · 04/01 10:10
Weekly Report: what happened at RLAY last week (0318-0322)?
Weekly Report · 03/25 10:12
Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction
TipRanks · 03/19 05:38
RSI Alert: Relay Therapeutics (RLAY) Now Oversold
NASDAQ · 03/18 15:56
Weekly Report: what happened at RLAY last week (0311-0315)?
Weekly Report · 03/18 10:11
Relay Therapeutics: Platform More Important Than Programs
Seeking Alpha · 03/13 06:50
RLAY Crosses Below Key Moving Average Level
NASDAQ · 03/11 15:49
Weekly Report: what happened at RLAY last week (0304-0308)?
Weekly Report · 03/11 10:09
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
5 Biotech Stocks With 26% Upside Potential or More
Five biotech stocks are poised for notable growth. Nvidia (NVDA) is the standout performer in the S&P 500 Index so far this year. The biotech industry may be headed for a comeback. Each of these stocks has room to rally 26% to Wall Street's mean price target.
Barchart · 03/07 13:13
Weekly Report: what happened at RLAY last week (0226-0301)?
Weekly Report · 03/04 10:11
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN)
Korro Bio received a Buy rating and a $120.00 price target from BMO Capital analyst today. Relay Therapeutics and Regeneron also received Buy ratings from analysts. 3 analysts just weighed in on the Healthcare sector with bullish sentiments. Korro Bio, Regeneron and Relay are most likely to make moves following insider activities.
TipRanks · 02/27 05:30
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
Barchart · 02/26 15:05
Relay Therapeutics: Strong Buy on Improved Financials and Promising Future Milestones
TipRanks · 02/26 11:18
More
Webull provides a variety of real-time RLAY stock news. You can receive the latest news about Relay Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.